Tag:
Aflibercept
Latest Headlines
Latest Headlines
Sanofi colorectal cancer contender Zaltrap suffers a PhIII trial setback
Sanofi and Regeneron's opened their update on the cancer drug Zaltrap (aflibercept) on a sweet note: The FDA has granted a priority review of their NDA for colorectal cancer.
Regeneron finally captures an FDA OK with new eye drug
Late on Friday Regeneron Pharmaceuticals ( $REGN ) scored a big win as it announced that the FDA has approved Eylea (aflibercept) for wet, age-related macular degeneration. But after pricing an
Sanofi lines up a growing slate of late-stage drug prospects
Few Big Pharma companies have done as much as Sanofi to change the game plan in R&D. And if you drill down into the company's second quarter report today, you'll find a snapshot of just how
What's the best strategy for working with FDA regulators?
Today FDA staffers published an even-handed evaluation of VEGF Trap Eye ( aflibercept ). As Bloomberg reports, the drug helps prevent vision loss just as well as a rival treatment on the market. And it
Sanofi preps for new pivotal trial of a blockbuster hopeful
One of the biggest pipeline setbacks Sanofi has experienced recently has been the failure of its high-profile Phase III breast cancer trial for iniparib back in January. Iniparib was the jewel in
Sanofi, Regeneron buoyed by Ph3 colon cancer success for aflibercept
Just weeks after Sanofi-Aventis and Regeneron ( $REGN ) reported that their cancer drug aflibercept stumbled in a late-stage study of non-small cell lung cancer, researchers gave a thumbs-up to their
Sanofi, Regeneron's aflibercept flunks PhIII trial
Big Pharma's development woes continue. Sanofi-Aventis ( $SNY ) and partner Regeneron have revealed that their non-small cell lung cancer drug aflibercept (VEGF Trap) given with the chemotherapy
Regeneron to shelve mid-stage cancer drug data
Citing problems with the number of patients recruited for a mid-stage clinical trial of the cancer drug aflibercept along with the fragile health of the patients involved, Regeneron Therapeutics and
Aflibercept misses endpoint in mid-stage study
Regeneron and Sanofi-Aventis announced that their experimental therapy aflibercept missed a
European pipeline likely to stay thin to 2009
GlaxoSmithKline appears to be best situated among the European pharma companies to weather the drought
